# GILEAD SCIENCES, INC.

Summary updated: 2026-10-04T09:50:10.252875Z
Canonical: https://finbar.com/research/companies/gilead-sciences

## Overview

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on virology, oncology and inflammation. Its portfolio includes treatments and prevention products for HIV, as well as medicines for liver disease, cancer and COVID-19; Biktarvy and Yeztugo are among its defining HIV products. The company describes its mission as discovering, developing and delivering innovative therapeutics for people with life-threatening diseases, while working to remove barriers to care and improve health equity. [1](https://app.finbar.com/go?id=P27643973)[2](https://app.finbar.com/go?id=P81920128)[3](https://app.finbar.com/go?id=P33546286)[4](https://www.gilead.com/company/policies-and-procedures)

Gilead reports more than 17,000 employees across 40-plus countries on six continents. It recorded $29.443 billion in revenue for 2025 and reported $7.803 billion for the second quarter of 2026. [5](https://www.gilead.com/careers/life-at-gilead)[6](https://app.finbar.com/go?id=P11515395)[7](https://app.finbar.com/go?id=T17188554)
[1](https://app.finbar.com/go?id=P27643973)[2](https://app.finbar.com/go?id=P81920128)[3](https://app.finbar.com/go?id=P33546286)[6](https://app.finbar.com/go?id=P11515395)[7](https://app.finbar.com/go?id=T17188554)[4](https://www.gilead.com/company/policies-and-procedures)[5](https://www.gilead.com/careers/life-at-gilead)

## Products & services

Gilead’s 2025 product sales were $28.915 billion, led by its HIV portfolio at $20.752 billion. Biktarvy, a once-daily complete HIV-1 treatment regimen, recorded $14.334 billion in sales, while Descovy recorded $2.758 billion. Other HIV products include Genvoya, Odefsey and Symtuza. Yeztugo is a twice-yearly HIV pre-exposure prophylaxis (PrEP) option; Sunlenca is used with other medicines to treat multidrug-resistant HIV-1.[8](https://app.finbar.com/go?id=T7619129)[9](https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm)[10](https://www.biktarvyhcp.com/)[11](https://www.gilead.com/-/media/files/pdfs/medicines/hiv/yeztugo/yeztugo_pi.pdf)[12](https://www.gilead.com/-/media/files/pdfs/medicines/hiv/sunlenca/sunlenca_pi.pdf)

Liver-disease products generated $3.217 billion in sales, including $1.272 billion for sofosbuvir/velpatasvir and $1.070 billion for Vemlidy. Epclusa (sofosbuvir/velpatasvir) treats chronic hepatitis C; Livdelzi is indicated for primary biliary cholangitis. Oncology sales were $3.236 billion: Yescarta ($1.495 billion) and Tecartus ($344 million) are CD19-directed autologous CAR-T cell therapies, and Trodelvy ($1.397 billion) is a Trop-2-directed antibody-drug conjugate. Veklury, an intravenous antiviral for COVID-19, recorded $911 million in sales; AmBisome, a liposomal amphotericin B antifungal, recorded $509 million. The 2025 filing reports product sales by product but not each product’s percentage of total sales; it separately reports $527 million in royalty, contract and other revenues.[8](https://app.finbar.com/go?id=T7619129)[13](https://app.finbar.com/go?id=P89607844)[14](https://app.finbar.com/go?id=P93837317)[9](https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm)[15](https://hcp.epclusa.com/)[16](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)[17](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/tecartus/tecartus-pi.pdf)[18](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf)[19](https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf)
[8](https://app.finbar.com/go?id=T7619129)[13](https://app.finbar.com/go?id=P89607844)[14](https://app.finbar.com/go?id=P93837317)[9](https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm)[10](https://www.biktarvyhcp.com/)[11](https://www.gilead.com/-/media/files/pdfs/medicines/hiv/yeztugo/yeztugo_pi.pdf)[12](https://www.gilead.com/-/media/files/pdfs/medicines/hiv/sunlenca/sunlenca_pi.pdf)[15](https://hcp.epclusa.com/)[16](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)[17](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/tecartus/tecartus-pi.pdf)[18](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf)[19](https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf)

## Geographic presence

In 2025, Gilead’s revenue totaled $29.443 billion: $20.876 billion from the United States (about 70.9%), $5.064 billion from Europe (17.2%), and $3.503 billion from the rest of the world (11.9%). Percentages are calculated from the reported regional amounts. The company operates in more than 35 countries worldwide. [8](https://app.finbar.com/go?id=T7619129)[20](https://app.finbar.com/go?id=P49479044)

Gilead is headquartered at 333 Lakeside Drive in Foster City, California; the site includes administrative, research and development, and manufacturing activities. [21](https://app.finbar.com/go?id=P35099628)[22](https://app.finbar.com/go?id=P12066238) Its listed administrative facilities are in Raleigh, North Carolina; Parsippany, New Jersey; Washington, D.C.; and Cork, Ireland. Research and development facilities are in Oceanside and Santa Monica, California; Frederick, Maryland; Philadelphia, Pennsylvania; Edmonton, Canada; Dublin, Ireland; and Cambridge and Oxford, United Kingdom. Manufacturing facilities are in El Segundo, La Verne, Oceanside, and Santa Monica, California; Frederick, Maryland; Edmonton, Canada; Cork, Ireland; and Hoofddorp, Netherlands. [23](https://app.finbar.com/go?id=P36169941)[24](https://app.finbar.com/go?id=P88095400)[25](https://app.finbar.com/go?id=P66188793)
[8](https://app.finbar.com/go?id=T7619129)[8](https://app.finbar.com/go?id=T7619129)[8](https://app.finbar.com/go?id=T7619129)[8](https://app.finbar.com/go?id=T7619129)[20](https://app.finbar.com/go?id=P49479044)[21](https://app.finbar.com/go?id=P35099628)[22](https://app.finbar.com/go?id=P12066238)[23](https://app.finbar.com/go?id=P36169941)[24](https://app.finbar.com/go?id=P88095400)[25](https://app.finbar.com/go?id=P66188793)

## Business segments

Gilead reports one operating segment, encompassing the company’s discovery, development and commercialization of medicines; management evaluates performance and allocates resources on an entity-wide basis. The sole reported segment represented 100% of FY2025 revenue, or $29.443 billion. [26](https://app.finbar.com/go?id=P59227028)

For revenue disaggregation—not separate reportable segments—FY2025 sales were grouped as HIV ($20.752 billion; approximately 70.5% of revenue), liver disease ($3.217 billion; 10.9%), Veklury ($911 million; 3.1%), oncology, including cell therapy ($3.236 billion; 11.0%), and other product sales ($799 million; 2.7%). Royalty, contract and other revenues were $527 million (1.8%). Percentages are calculated against total FY2025 revenue of $29.443 billion and rounded to one decimal place. [8](https://app.finbar.com/go?id=T7619129)
[26](https://app.finbar.com/go?id=P59227028)[8](https://app.finbar.com/go?id=T7619129)[8](https://app.finbar.com/go?id=T7619129)[8](https://app.finbar.com/go?id=T7619129)[8](https://app.finbar.com/go?id=T7619129)[8](https://app.finbar.com/go?id=T7619129)[8](https://app.finbar.com/go?id=T7619129)[8](https://app.finbar.com/go?id=T7619129)

## Company history

Gilead Sciences was founded in 1987 by Michael L. Riordan. Early milestones included FDA clearance of Vistide in 1996, described by Gilead as its first commercial product, and FDA approval of Viread for HIV treatment in 2001. Gilead also developed Tamiflu, which it licensed to Roche in 1996 before its FDA approval in 1999. [27](https://www.gilead.com/news/news-details/1997/donald-h-rumsfeld-named-chairman-of-gilead-sciences) [28](https://www.gilead.com/news/news-details/1996/fda-grants-marketing-clearance-of-gileads-vistide-for-the-treatment-of-cmv-retinitis-in-patients-with-aids) [29](https://www.gilead.com/news/news-details/2001/us-fda-approves-gilead-sciences-anti-hiv-drug-viread) [30](https://www.gilead.com/news/news-details/2005/gilead-and-roche-end-tamiflur-dispute-expanded-collaboration-includes-gilead-role-in-oversight-of-manufacturing-and-commercialization)

Gilead expanded through acquisitions including NeXstar in 1999, Triangle Pharmaceuticals in 2003, and Pharmasset in 2012. The Pharmasset acquisition preceded a major expansion in hepatitis C treatment: the FDA approved Sovaldi in 2013 and Harvoni in 2014. In 2016, John F. Milligan succeeded longtime CEO John C. Martin; Daniel O’Day became chairman and CEO in 2019. [31](https://www.gilead.com/news/news-details/1999/gilead-acquisition-of-nexstar-completed) [32](https://www.gilead.com/news/news-details/2003/gilead-sciences-completes-acquisition-of-triangle-pharmaceuticals) [33](https://www.gilead.com/news/news-details/2012/gilead-sciences-completes-acquisition-of-pharmasset-inc) [34](https://www.gilead.com/news/news-details/2013/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c) [35](https://www.gilead.com/news/news-details/2014/us-food-and-drug-administration-approves-gileads-harvoni-ledipasvirsofosbuvir-the-first-once-daily-single-tablet-regimen-for-the-treatment-of-genotype-1-chronic-hepatitis-c) [36](https://www.gilead.com/news/news-details/2016/gileads-john-c-martin-phd-to-assume-role-of-executive-chairman-of-the-board-john-f-milligan-phd-to-be-appointed-chief-executive-officer-and-director) [37](https://www.gilead.com/news/news-details/2018/gilead-sciences-names-daniel-oday-chairman-and-chief-executive-officer)

In 2017, Gilead completed its acquisition of Kite Pharma, expanding into cell therapy, and in 2018 the FDA approved its HIV treatment Biktarvy. The company expanded further with its 2020 acquisition of Immunomedics and FDA approval of Veklury for COVID-19 treatment. In 2025, the FDA approved Yeztugo for HIV prevention; Gilead described it as the first FDA-approved HIV prevention option offering six months of protection. [38](https://www.gilead.com/news/news-details/2017/gilead-sciences-completes-acquisition-of-kite-pharma-inc) [39](https://www.gilead.com/news/news-details/2018/us-food-and-drug-administration-approves-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv-1-infection) [40](https://www.gilead.com/news/news-details/2020/gilead-sciences-completes-acquisition-of-immunomedics-inc) [41](https://www.gilead.com/news/news-details/2020/us-food-and-drug-administration-approves-gileads-antiviral-veklury-remdesivir-for-treatment-of-covid-19) [42](https://www.gilead.com/news/news-details/2025/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection)
[27](https://www.gilead.com/news/news-details/1997/donald-h-rumsfeld-named-chairman-of-gilead-sciences)[28](https://www.gilead.com/news/news-details/1996/fda-grants-marketing-clearance-of-gileads-vistide-for-the-treatment-of-cmv-retinitis-in-patients-with-aids)[29](https://www.gilead.com/news/news-details/2001/us-fda-approves-gilead-sciences-anti-hiv-drug-viread)[30](https://www.gilead.com/news/news-details/2005/gilead-and-roche-end-tamiflur-dispute-expanded-collaboration-includes-gilead-role-in-oversight-of-manufacturing-and-commercialization)[31](https://www.gilead.com/news/news-details/1999/gilead-acquisition-of-nexstar-completed)[32](https://www.gilead.com/news/news-details/2003/gilead-sciences-completes-acquisition-of-triangle-pharmaceuticals)[33](https://www.gilead.com/news/news-details/2012/gilead-sciences-completes-acquisition-of-pharmasset-inc)[34](https://www.gilead.com/news/news-details/2013/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c)[35](https://www.gilead.com/news/news-details/2014/us-food-and-drug-administration-approves-gileads-harvoni-ledipasvirsofosbuvir-the-first-once-daily-single-tablet-regimen-for-the-treatment-of-genotype-1-chronic-hepatitis-c)[36](https://www.gilead.com/news/news-details/2016/gileads-john-c-martin-phd-to-assume-role-of-executive-chairman-of-the-board-john-f-milligan-phd-to-be-appointed-chief-executive-officer-and-director)[37](https://www.gilead.com/news/news-details/2018/gilead-sciences-names-daniel-oday-chairman-and-chief-executive-officer)[38](https://www.gilead.com/news/news-details/2017/gilead-sciences-completes-acquisition-of-kite-pharma-inc)[39](https://www.gilead.com/news/news-details/2018/us-food-and-drug-administration-approves-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv-1-infection)[40](https://www.gilead.com/news/news-details/2020/gilead-sciences-completes-acquisition-of-immunomedics-inc)[41](https://www.gilead.com/news/news-details/2020/us-food-and-drug-administration-approves-gileads-antiviral-veklury-remdesivir-for-treatment-of-covid-19)[42](https://www.gilead.com/news/news-details/2025/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection)

## Sources

1. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P27643973)
2. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P81920128)
3. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P33546286)
4. [www.gilead.com](https://www.gilead.com/company/policies-and-procedures)
5. [www.gilead.com](https://www.gilead.com/careers/life-at-gilead)
6. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P11515395)
7. [GILEAD SCIENCES, INC. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T17188554)
8. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T7619129)
9. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm)
10. [www.biktarvyhcp.com](https://www.biktarvyhcp.com/)
11. [www.gilead.com](https://www.gilead.com/-/media/files/pdfs/medicines/hiv/yeztugo/yeztugo_pi.pdf)
12. [www.gilead.com](https://www.gilead.com/-/media/files/pdfs/medicines/hiv/sunlenca/sunlenca_pi.pdf)
13. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P89607844)
14. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P93837317)
15. [hcp.epclusa.com](https://hcp.epclusa.com/)
16. [www.gilead.com](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)
17. [www.gilead.com](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/tecartus/tecartus-pi.pdf)
18. [www.gilead.com](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf)
19. [www.gilead.com](https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf)
20. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P49479044)
21. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P35099628)
22. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P12066238)
23. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P36169941)
24. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P88095400)
25. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P66188793)
26. [GILEAD SCIENCES, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P59227028)
27. [www.gilead.com](https://www.gilead.com/news/news-details/1997/donald-h-rumsfeld-named-chairman-of-gilead-sciences)
28. [www.gilead.com](https://www.gilead.com/news/news-details/1996/fda-grants-marketing-clearance-of-gileads-vistide-for-the-treatment-of-cmv-retinitis-in-patients-with-aids)
29. [www.gilead.com](https://www.gilead.com/news/news-details/2001/us-fda-approves-gilead-sciences-anti-hiv-drug-viread)
30. [www.gilead.com](https://www.gilead.com/news/news-details/2005/gilead-and-roche-end-tamiflur-dispute-expanded-collaboration-includes-gilead-role-in-oversight-of-manufacturing-and-commercialization)
31. [www.gilead.com](https://www.gilead.com/news/news-details/1999/gilead-acquisition-of-nexstar-completed)
32. [www.gilead.com](https://www.gilead.com/news/news-details/2003/gilead-sciences-completes-acquisition-of-triangle-pharmaceuticals)
33. [www.gilead.com](https://www.gilead.com/news/news-details/2012/gilead-sciences-completes-acquisition-of-pharmasset-inc)
34. [www.gilead.com](https://www.gilead.com/news/news-details/2013/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c)
35. [www.gilead.com](https://www.gilead.com/news/news-details/2014/us-food-and-drug-administration-approves-gileads-harvoni-ledipasvirsofosbuvir-the-first-once-daily-single-tablet-regimen-for-the-treatment-of-genotype-1-chronic-hepatitis-c)
36. [www.gilead.com](https://www.gilead.com/news/news-details/2016/gileads-john-c-martin-phd-to-assume-role-of-executive-chairman-of-the-board-john-f-milligan-phd-to-be-appointed-chief-executive-officer-and-director)
37. [www.gilead.com](https://www.gilead.com/news/news-details/2018/gilead-sciences-names-daniel-oday-chairman-and-chief-executive-officer)
38. [www.gilead.com](https://www.gilead.com/news/news-details/2017/gilead-sciences-completes-acquisition-of-kite-pharma-inc)
39. [www.gilead.com](https://www.gilead.com/news/news-details/2018/us-food-and-drug-administration-approves-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv-1-infection)
40. [www.gilead.com](https://www.gilead.com/news/news-details/2020/gilead-sciences-completes-acquisition-of-immunomedics-inc)
41. [www.gilead.com](https://www.gilead.com/news/news-details/2020/us-food-and-drug-administration-approves-gileads-antiviral-veklury-remdesivir-for-treatment-of-covid-19)
42. [www.gilead.com](https://www.gilead.com/news/news-details/2025/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.